InduPro Therapeutics Collaborates with Eli Lilly in ~$950M Oncology Therapeutic Discovery Deal

Shots: InduPro has entered into a global strategic collaboration & licensing agreement with Eli Lilly to discover novel oncology treatments using InduPro’s proximity-guided platform Lilly will gain access to InduPro’s AI/ML-enabled MInt platform, with InduPro leading early discovery to identify co-target pairs & advance bispecific & multispecific antibody programs from the collaboration As per the…

ByRidhi RastogiJanuary 8, 2026

NEWS

Nimbus Therapeutics and Eli Lilly Enter ~$1.3B Deal to Develop Oral Metabolic Therapies

Shots: Nimbus has entered into a multi-year research collaboration & exclusive, worldwide license agreement with Eli Lilly to develop a novel oral treatment for obesity & other metabolic diseases Building on their prior AMPK cardiometabolic collaboration, Nimbus & Lilly have entered into a new partnership applying Nimbus’ computational chemistry & structure-based design to an…

ByRidhi RastogiJanuary 7, 2026

NEWS

Adlai Nortye Licenses AN9025 to ASK Pharm in a ~$230M Deal

Shots: Adlai Nortye has granted ASK Pharm exclusive rights to develop, manufacture, & commercialize AN9025 in mainland China, Hong Kong & Macao, with Adlai retaining rights in other regions As per the deal, Adlai will receive ~$230M, incl. >$20M in upfront & near-term milestone, plus tiered royalties ranging from a high single-digit to mid-teens %…

ByRidhi RastogiDecember 29, 2025

NEWS

Transcenta and EirGenix Collaborate to Advance Integrated Continuous Biomanufacturing Technologies

Shots: EirGenix has entered into a strategic collaboration and non-exclusive licensing agreement with Transcenta for its Highly Intensified Continuous Bioprocessing (HiCB) platform Under the agreement, Transcenta will grant EirGenix a non-exclusive license to its HiCB platform, incl. continuous perfusion & integrated hybrid continuous purification process technologies, as well as documentation, know-how & regulatory support to…

ByRidhi RastogiDecember 29, 2025

NEWS

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs

Shots: ABL Bio has secured a total of $55M, incl. $40M upfront & $15M in equity investment, from Eli Lilly under their ~$2.602B license, research & collaboration agreement Under the deal, ABL Bio & Eli Lilly are jointly advancing multiple therapeutic candidates across diverse modalities, leveraging ABL Bio’s Grabody platform for collaborative research & development…

ByRidhi RastogiDecember 29, 2025

NEWS

Italfarmaco and JCR Pharmaceuticals Partner to Commercialize Givinostat in Japan

Shots: Italfarmaco has entered into an exclusive licensing agreement with JCR Pharmaceuticals for the development and commercialisation of givinostat in Japan As per the deal, JCR will secure exclusive rights to commercialize givinostat, marketed as Duvyzat in US, EU & UK, for Duchenne muscular dystrophy (DMD) in Japan & will lead local execution of clinical…

ByRidhi RastogiDecember 26, 2025

NEWS

Rectify Pharmaceuticals and Boehringer Ingelheim Partner to Develop Small Molecules for Chronic Kidney Disease (CKD)

Shots: Rectify has entered into a strategic research & licensing agreement with BI to accelerate the development of small molecule therapies for CKD & other conditions Collaboration will leverage Rectify’s positive functional modulators (PFM) platform to develop oral small molecules that restore or enhance ABCC6 function, targeting pathologic calcification to slow disease progression in CKD, Pseudoxanthoma elasticum,…

ByRidhi RastogiDecember 24, 2025

NEWS

Ipsen Signs ~$1.06B Deal with Simcere Zaiming for SIM0613

Shots: Ipsen has entered into an exclusive licensing agreement with Simcere Zaiming for SIM0613 to treat solid tumors with the highest unmet needs Ipsen will secure global rights to SIM0613 outside Greater China, gain manufacturing rights after technology transfer, & assume responsibility for all development activities beyond Greater China, incl. P-I preparation & IND/CTA submissions As…

ByRidhi RastogiDecember 24, 2025

NEWS

Windward Bio Secures Exclusive Rights to WIN027 from Qyuns Therapeutics in a ~$700M Deal

Shots: Windward Bio via its affiliate, LE2025 Therapeutics, has entered into a licensing agreement with Qyuns to develop & commercialize WIN027 (QX027N; anti-TSLPxIL-13 bsAb) As per the deal, Windward will obtain exclusive rights to develop, manufacture, & commercialize WIN027 outside of China, with Qyuns receiving an upfront payment, equity, & development, regulatory, & commercial milestones,…

ByRidhi RastogiDecember 24, 2025

NEWS

Jacobio Pharma Forge ~$2B+ Partnership with AstraZeneca for JAB-23E73

Shots: Jacobio Pharma entered a global exclusive licensing agreement with AstraZeneca for JAB-23E73, granting AstraZeneca exclusive development & commercialization rights outside China, while both companies will jointly develop & commercialize in China As per the deal, Jacobio will receive $100M upfront, and is eligible up to $1.91B in development & commercial milestones, and tiered royalties…

ByRidhi RastogiDecember 22, 2025

InduPro Therapeutics Collaborates with Eli Lilly in ~$950M Oncology Therapeutic Discovery Deal

Nimbus Therapeutics and Eli Lilly Enter ~$1.3B Deal to Develop Oral Metabolic Therapies

Adlai Nortye Licenses AN9025 to ASK Pharm in a ~$230M Deal

Transcenta and EirGenix Collaborate to Advance Integrated Continuous Biomanufacturing Technologies

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs

Italfarmaco and JCR Pharmaceuticals Partner to Commercialize Givinostat in Japan

Rectify Pharmaceuticals and Boehringer Ingelheim Partner to Develop Small Molecules for Chronic Kidney Disease (CKD)

Ipsen Signs ~$1.06B Deal with Simcere Zaiming for SIM0613

Windward Bio Secures Exclusive Rights to WIN027 from Qyuns Therapeutics in a ~$700M Deal

Jacobio Pharma Forge ~$2B+ Partnership with AstraZeneca for JAB-23E73

Contact US

FOLLOW US